Tecnologie rivoluzionarie per le proteine ​​di fusione Italia

Currently, many therapeutic proteins that have formed market scale are based on fusion protein technology. Fusion proteins utilize genetic engineering and other techniques to combine functional proteins with fusion partners, thereby enhancing their activity and tolerance.

Based on a strong microbial system, Yaohai Bio-Pharma boasts more than a decade of experience in developing fusion proteins, especially for long-acting formulations. Within very short delivery deadlines, the delivery rate of Yaohai Bio-Pharma can reach 99%. Yaohai Bio-Pharma can fulfill clients' requirements from strain engineering to fill and finish.

Leveraging the experience of the strong expert team at Yaohai Bio-Pharma, the following is a summarized introduction to several classic fusion protein technologies:

Immunoglobulin Fusion Technology

Fc Fusion: Utilizes the Fc segment of immunoglobulin IgG as a fusion partner, increasing molecular weight and extending half-life through the FcRn-mediated recycling mechanism, while possessing multiple biological functions. Multiple Fc fusion protein drugs have been marketed.

Fv Fusion: Utilizes the variable region of immunoglobulins, which can reduce the size of fusion proteins but may present stability issues. Stability is improved through methods such as polypeptide linkers or covalent disulfide bonds.

Antibody-Enzyme Fusion Proteins: Fusion proteins combine enzymes and antibodies that target enzyme prodrugs to tumor sites, activating cell death pathways with relatively low toxicity.

Recombinant Fusion Proteins Based on HSA (Human Serum Albumin）

HSA is the most abundant protein in human plasma, with a half-life of 20 days. Utilizing HSA as a fusion choice offers a flexible approach to generating therapeutic proteins with extended half-lives. This technology prolongs the half-life, enhances protein stability, and reduces immunogenicity.

XTEN Fusion Protein Technology

XTEN is an unstructured, biodegradable protein polymer that increases the half-life of therapeutic peptides and proteins. It has been used in the development of multiple fusion protein drugs, such as growth hormone XTEN fusion proteins.

CTP Fusion Protein Technology

CTP is the carboxyl-terminal peptide of the beta subunit of human chorionic gonadotropin, which increases the sialic acid content of recombinant fusion proteins, extends half-life, and has low immunogenicity. It has been used in the development of long-acting fertility drugs such as Elonva.

ELP (Elastin-Like Peptide) Fusion Protein Technology

ELP is an engineered repetitive protein with inverse phase transition properties that can improve drug pharmacokinetics. It has been used in the development of long-acting formulations of insulin and GLP-1.

Transferrin Fusion Protein Technology

Transferrin is a highly abundant serum glycoprotein with a long half-life and a transferrin receptor-mediated recycling mechanism. It can serve as a drug carrier for treating brain diseases.

Fusion protein technology improves pharmacokinetic characteristics, making drugs more efficient and requiring less dosage. Fc fusion and HSA fusion technologies are widely used, but other technologies such as XTEN, CTP, ELP, and transferrin have also made significant progress, promising excellent therapeutic effects for patients worldwide.Yaohai Biopharmaceuticals' extensive experience in recombinant fusion protein technology can facilitate your development in the biological field!

Yaohai is also actively seeking institutional or individual global partners. Yaohai can offer the most competitive compensation in the industry. If you have any questions, please feel free to contact us at [email protected]